Category: Boston Scientific
Spinal devices maker Vexim appoints as its director of marketing Sandrine Carle, a veteran of spinal operations at medtech giant Medtronic.
French spinal devices maker Vexim (EPA:ALVXM) this month welcome Medtronic (NYSE:MDT) veteran Sandrine Carle as its director of marketing.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Medtech titan Boston Scientific provides a check on a raft of pending lawsuits, with pelvic mesh lawsuits still on the rise, Guidant lawsuits diminishing and Medtronic lobbing a new blow over renal denervation patents.
Massachusetts medical device giant Boston Scientific (NYSE:BSX) has dozen of legal irons in the fire at any given moment, some making forward progress while others cast an ominous shadow.
Some 650 lawsuits filed in an Oklahoma court over its pelvic mesh products ought to be treated as a mass action in federal court, Johnson & Johnson subsidiary Ethicon argued this week.
The plaintiffs in some 650 product liability lawsuits filed in an Oklahoma court over Ethicon's pelvic mesh products are improperly looking to exclude them from mass action status, the Johnson & Johnson (NYSE:JNJ) subsidiary argued this week in a federal appeals court.
The Philadelphia Court of Common Pleas establishes a mass tort for all pelvic mesh lawsuits filed in its jurisdiction.
A Pennsylvania state judge ordered the creation of a mass tort this week to collect product liability lawsuits filed over pelvic mesh products against some of the largest names in medical devices.
Judge Arnold New, director of the Complex Litigation Center at the Philadelphia Court of Common Pleas, ordered Feb. 11 that "all currently filed pelvic mesh matters shall be transferred to the Complex Litigation Center Pelvic Mesh Mass Tort Program" for coordination, according to court documents.
Medtronic touts the 1st U.S. implantation in the investigational device exemption trial of its Micra leadless pacemaker.
Medtronic (NYSE:MDT) said the 1st patient in a clinical trial of its its Micra pacemaker was implanted with the vitamin-sized device, which does not use wires threaded through blood vessels to regulate heart rhythm.
Medtronic's most recent quarterly results suggest that the medtech monolith could be losing ground to arch-rivals Boston Scientific and St. Jude Medical in the cardiac rhythm management market.
Revenues from Medtronic's (NYSE:MDT) bread-and-butter cardiac rhythm management and spine segments were down during its fiscal 3rd quarter, suggesting that the world's largest pure-play medical device maker lost share to its rivals during the quarter.